多发性骨髓瘤骨病的机制研究及治疗进展

doi:10.11904/j.issn.1002-3070.2017.03.011

实用肿瘤学杂志 ›› 2017, Vol. 31 ›› Issue (3): 246-249.doi: 10.11904/j.issn.1002-3070.2017.03.011

多发性骨髓瘤骨病的机制研究及治疗进展

李文君，郭艳秋，高玉娟综述，苏雁华审校

哈尔滨医科大学附属第一医院血液内科(哈尔滨 150001)

收稿日期:2016-11-28 出版日期:2017-06-28 发布日期:2017-07-04
通讯作者: 苏雁华,E-mail:suyanhua163@163.com
作者简介:李文君,女,(1990-),硕士研究生,从事血液科恶性疾病及出凝血疾病的研究
基金资助:
黑龙江省博士后科研启动金(LBH-Q10029)

Advarces in mechanism and treatment of multiple myeloma bone disease

LI Wenjun,GUO Yanqiu,GAO Yujuan,SU Yanhua

The First Affiliated Hospital of Harbin Medical University,Harbin 150001,China

Received:2016-11-28 Online:2017-06-28 Published:2017-07-04

摘要/Abstract

摘要： 多发性骨髓瘤是血液内科较常见的恶性疾病,其以恶性浆细胞在骨髓中过度增殖和积累为特征,产生大量单克隆免疫球蛋白及其片段,导致终末器官的损害。其中约80%的患者合并有多发性骨髓瘤骨病(MBD),从而严重影响了患者的生活质量及疾病预后。研究发现成骨细胞受抑、破骨细胞激活为其主要发病原因,而多种细胞因子及通路影响了这一机制的发生。本文就MBD发生、发展的最新因素及治疗做一综述。

关键词: 多发性骨髓瘤, 多发性骨髓瘤骨病, 成骨细胞, 破骨细胞

Abstract: Multiple myeloma is a more common malignant disease in blood medicine,which is characterized by hyper-proliferation and accumulation of malignant plasma cells in the bone marrow,resulting in a large number of monoclonal immunoglobulins and their fragments,leading to damage to the terminal organs.Of which about 80% of patients have multiple myeloma bone diseases(MBD),which seriously affected the quality of life and prognosis of patients.We have found that the main cause of MBD are contributed to inhibition of osteoblasts,activation of osteoclast and affecting the occurrence by a variety of cytokines and pathways.This article will review and introduce the occurrence and development of MBD related to the latest factors and treatment.

Key words: Multiple myeloma, Myeloma bone disease, Osteoblast, Osteoclast

中图分类号:

R733.3

李文君，郭艳秋，高玉娟综述，苏雁华审校. 多发性骨髓瘤骨病的机制研究及治疗进展[J]. 实用肿瘤学杂志, 2017, 31(3): 246-249.

LI Wenjun,GUO Yanqiu,GAO Yujuan,SU Yanhua. Advarces in mechanism and treatment of multiple myeloma bone disease[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 246-249.

参考文献

1 Eda H,Santo L,David Roodman G,et al.Bone disease in multiple myeloma[J].Cancer Treat Res,2016,169:251-270.
2 Bonewald L.The amazing osteocyte[J].Journal of Bone and Mineral Research,2011,26(2):229-238.
3 Yamagishi T,Kawashima H,Ogose A,et al.Receptor-activator of nuclear KappaB ligand expression as a new therapeutic target in primary bone tumors[J].PLoS One,2016,10;11(5):e0154680.
4 Kushlinskiǐ NE,Timofeev IuS,Gershteǐn ES,et al.Clinical perspectives of the study of RANK/RANKL/OPG system components in primary and metastatic bone tumor[J].Vopr Onkol,2014,60(4):413-421.
5 Walker RE,Lawson MA,Buckle CH,et al.Myeloma bone disease:pathogenesis,current treatments and future targets[J].British Medical Bulletin,2014,111(1):117-138.
6 Colombo M,Mirandola L,Platonova N,et al.Notch-directed microenvironment reprogramming in myeloma:a single path to multiple outcomes[J].Leukemia,2013,27(5):1009-1018.
7 Yin L,Velazquez OC,Liu ZJ.Notch signaling:emerging molecular targets for cancer therapy[J].Biochemical Pharmacology,2010,80(5):690-701.
8 Colombo M,Galletti S,Garavelli S,et al.Notch signaling deregulation in multiple myeloma:A rational molecular target[J].Oncotarget,2015,6(29):26826-26840.
9 Colombo M,Thümmler K,Mirandola L,et al.Notch signaling drives multiple myeloma induced osteoclastogenesis[J].Oncotarget,2014,5(21):10393-10406.
10 Zanotti S,Smerdelramoya A,Stadmeyer L,et al.Notch inhibits osteoblast differentiation and causes osteopenia[J].Endocrinology,2008,149(8):3890-3899.
11 Asano J,Nakano A,Oda A,et al.The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells[J].Leukemia,2011,25(7):1182-1188.
12 Hiasa M,Teramachi J,Oda A,et al.Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma[J].Leukemia,2015,29(1):207-217.
13 Reya T,Clevers H.Wnt signalling in stem cells and cancer[J].Nature,2005,434(7035):843-850.
14 Kestler HA,Kühl M.From individual Wnt pathways towards a Wnt signalling network[J].Philos Trans R Soc Lond B Biol Sci,2008,363(1495):1333-1347.
15 Rachner TD,Gbel A,Benad-Mehner P,et al.Dickkopf-1 as a mediator and novel target in malignant bone disease[J].Cancer Letters,2014,346(2):172-177.
16 Takahashi N,Maeda K,Ishihara A,et al.Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals[J].Front Biosci,2011,16:21-30.
17 Sottnik JL,Hall CL,Zhang J,et al.Wnt and Wnt inhibitors in bone metastasis[J].Bonekey Rep,2012,1:101.
18 Delgado-Calle J,Sato AY,Bellido T.Role and mechanism of action of sclerostin in bone[J].Bone,2017,96:29-37.
19 Ghali O,Chauveau C,Hardouin P,et al.TNF-alpha′s effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression[J].J Bone Miner Res,2010,25(7):1616-1626.
20 Chawla S,Henshaw R,Seeger L,et al.Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone:interim analysis of an open-label,parallel-group,phase 2 study[J].Lancet Oncology,2013,14(9):901-908.
21 Wang JH,Zhang Y,Li HY,et al.Dickkopf-1 negatively regulates the expression of osteoprotegerin,a key osteoclastogenesis inhibitor,by sequestering Lrp6 in primary and metastatic lytic bone lesions[J].Medicine,2016,95(24):e3767.
22 Ri M.Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy[J].Rinsho Ketsueki,2016,57(5):537-545.
23 翁翔,顾超,翟丽娜,等.硼替佐米在多发性骨髓瘤治疗中的应用[J].中国肿瘤,2014,23(8):674-679.
24 Anderson G,Gries M,Kurihara N,et al.Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1[J].Blood,2006,107(8):3098-105.
25 Wang J,Guo H,Zhou X.Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients[J].Onco Targets Ther,2015,8:1277-1284.

[1]	李林，毛朝明，周建明，高健青. ¹⁸F-FDG PET-CT显像在多发性骨髓瘤中的影像表现[J]. 实用肿瘤学杂志, 2017, 31(3): 222-227.
[2]	赵郁，朱晓婷，王轶楠. ω-3多不饱和脂肪酸诱导多发性骨髓瘤细胞凋亡及抗增殖机制的研究[J]. 实用肿瘤学杂志, 2016, 30(6): 516-522.
[3]	操梅林, 徐燕丽, 张磊. 多发性骨髓瘤化疗后发生急性髓系白血病一例并文献复习[J]. 实用肿瘤学杂志, 2015, 29(6): 536-539.
[4]	王燕, 刘爱春. 多发性骨髓瘤的治疗进展[J]. 实用肿瘤学杂志, 2012, 26(2): 183-187.
[5]	王(王争);周义林;张军盛;徐惠琴. 多发性骨髓瘤病人99m Tc-MIBI显像的临床价值[J]. 实用肿瘤学杂志, 2008, 22(05): 441-443.
[6]	丁汀;裘小萍;顾磊;王应贵;陈峪;陈兆军;蒋挺英. 多发性骨髓瘤血小板生成素及受体初步研究[J]. 实用肿瘤学杂志, 2005, 19(03): 178-180.
[7]	袁志军;肖立新;欧阳沙西. 多发性骨髓瘤并发肾脏损害误诊原因分析[J]. 实用肿瘤学杂志, 2002, 16(04): 267-268.
[8]	陆海波;孙秀威;于雁. 25例多发性骨髓瘤的诊治分析[J]. 实用肿瘤学杂志, 2002, 16(04): 303-304.

多发性骨髓瘤骨病的机制研究及治疗进展

Advarces in mechanism and treatment of multiple myeloma bone disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价